Irish researchers are developing CASPDx CRC, a novel blood test designed to detect colorectal cancer (CRC) through identifying specific inflammatory markers. This non-invasive screening method, currently undergoing clinical validation, aims to improve early detection rates and address the limitations of existing screening options like colonoscopies and stool-based kits, potentially impacting global mortality rates from this prevalent cancer.
Colorectal cancer is a growing global health concern, particularly among younger adults. Current screening methods often face barriers to uptake due to their invasive nature or perceived unpleasantness, leading to delayed diagnoses and poorer outcomes. The CASPDx CRC test offers a potentially transformative solution by providing a simpler, more accessible, and potentially more accurate method for early detection.
In Plain English: The Clinical Takeaway
- Early Detection Matters: Finding colorectal cancer early, before symptoms appear, dramatically increases the chances of successful treatment and survival.
- Blood Test Simplicity: This new test aims to replace or supplement less appealing screening methods like colonoscopies and stool tests with a simple blood draw.
- Inflammation as a Signal: The test works by detecting specific inflammatory markers in the blood that are elevated during the development and progression of colorectal cancer.
The Science Behind CASPDx CRC: Inflammation and Cancer Development
The CASPDx CRC test, spearheaded by researchers at Trinity College Dublin, Dublin City University, and University College Dublin, centers on the role of inflammation in colorectal cancer. Inflammation, while a crucial component of the body’s immune response and tissue repair mechanisms, can also inadvertently contribute to cancer growth, progression, and metastasis. Dr. Emma Creagh, associate professor in biochemistry at Trinity College Dublin and Scientific Lead for CASPDx, explains, “Our research has identified specific inflammation markers that turn into increased during CRC development and progression. The blood test we are developing will identify possible CRC patients by detecting these inflammatory markers directly from their blood sample.” These markers aren’t simply indicators of inflammation; they represent specific pathways activated during tumorigenesis. Specifically, the research focuses on identifying circulating cytokines and chemokines – signaling molecules that regulate immune cell activity – that are dysregulated in CRC patients. This approach differs from traditional biomarker detection, which often focuses on tumor-specific antigens. The test is currently in the clinical validation and immunoassay development phases, with patient recruitment underway at Bowel Screen Centres in the HSE Dublin and South East region.
Addressing the Global Burden of Colorectal Cancer
Colorectal cancer is the second leading cause of cancer mortality worldwide, accounting for approximately 1.1 million new cases and 694,000 deaths in 2020, according to the World Health Organization (WHO Colorectal Cancer Fact Sheet). Despite being highly treatable when detected early – with a five-year survival rate exceeding 90% for localized disease – over 60% of cases are diagnosed at a late stage. This delay in diagnosis is often attributed to inadequate screening rates and the limitations of current screening modalities. The current standard of care involves fecal occult blood tests (FOBT) and colonoscopies. FOBT, while non-invasive, has a relatively low sensitivity, meaning it can miss early-stage cancers. Colonoscopies, while highly accurate, are invasive, require bowel preparation, and carry a small risk of complications. The CASPDx CRC test aims to bridge this gap by offering a more patient-friendly and potentially more accurate screening option. The economic burden of CRC is also substantial; the disease is estimated to have cost the EU €19 billion in 2020. With nearly 120 million unscreened individuals across the US and EU, the need for a transformative solution is pressing.
Funding, Validation, and the Path to Commercialization
The development of the CASPDx CRC test is being supported by €670,000 in funding from Enterprise Ireland. This funding will enable the research team to hire personnel to complete the test’s development and clinical validation. The team anticipates launching the test and establishing a spin-out company by the end of 2027. Clinical validation is a crucial step, involving rigorous testing of the test’s accuracy and reliability in a large cohort of patients. This process typically involves multiple phases, starting with small-scale feasibility studies and progressing to larger, multi-center trials. The test will need to demonstrate high sensitivity (the ability to correctly identify individuals with CRC) and specificity (the ability to correctly identify individuals without CRC) to be considered clinically useful. The researchers are also working to optimize the immunoassay – the biochemical test used to detect the inflammatory markers – to ensure its accuracy and reproducibility.
| Phase | Objective | Estimated Timeline |
|---|---|---|
| Phase 1 (Completed) | Biomarker Identification & Assay Development | 2023-2024 |
| Phase 2 (Current) | Clinical Validation (Sensitivity & Specificity) | 2025-2026 |
| Phase 3 | Large-Scale Multi-Center Trials | 2026-2027 |
| Phase 4 | Regulatory Approval & Commercial Launch | Late 2027 |
“The potential for a reliable blood-based screening test is a significant step forward,” said Prof Glen Doherty, Consultant Gastroenterologist at St Vincent’s University Hospital. “Beyond simply detecting bowel cancer at an earlier, more treatable stage, these tests could help us identify which patients truly require a colonoscopy following a positive stool test. By improving our diagnostic accuracy through a simple blood draw, we could reduce the number of unnecessary colonoscopies, ensuring that hospital resources are focused on the patients who need them most.”
The Rising Incidence of Early-Onset Colorectal Cancer
A particularly concerning trend is the increasing incidence of early-onset colorectal cancer (diagnosis before age 50). Rates of this form of the disease have almost doubled over the past 30 years, and projections indicate that by 2030, early-onset CRC will be a leading cause of cancer-related deaths in adults aged 20-49. This rise is attributed to a complex interplay of factors, including changes in diet, lifestyle, and the gut microbiome. Early-onset CRC often presents with more aggressive features and is frequently diagnosed at a later stage due to lower screening rates, as most screening programs start at age 50 (or 58 in Ireland). This underscores the importance of developing screening tools that are accessible and appealing to younger adults.
“We are seeing a concerning rise in colorectal cancer among younger adults, and This represents likely due to a combination of factors, including dietary changes, obesity, and alterations in the gut microbiome. Early detection is crucial for improving outcomes in this population.” – Dr. Rebecca Siegel, Strategic Director, Surveillance Research, American Cancer Society (American Cancer Society Report)
Contraindications & When to Consult a Doctor
While the CASPDx CRC test is anticipated to be safe and well-tolerated, it’s significant to note that it is a screening test, not a diagnostic test. A positive result on the CASPDx CRC test will require further investigation, typically with a colonoscopy, to confirm the diagnosis. Individuals with a strong family history of colorectal cancer, known genetic predispositions (such as Lynch syndrome or familial adenomatous polyposis), or a history of inflammatory bowel disease should continue to follow the screening recommendations of their healthcare provider, regardless of the availability of the CASPDx CRC test. If you experience any symptoms of colorectal cancer, such as persistent changes in bowel habits, rectal bleeding, abdominal pain, or unexplained weight loss, consult a doctor immediately. Do not rely solely on the results of a blood test for diagnosis.
The development of the CASPDx CRC test represents a significant step forward in the fight against colorectal cancer. By offering a simpler, more accessible, and potentially more accurate screening option, this innovative blood test has the potential to save lives and reduce the global burden of this devastating disease. Continued research and clinical validation will be essential to ensure its widespread adoption and impact.
References
- World Health Organization. (2023). Colorectal cancer. https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer
- American Cancer Society. (2023). Colorectal cancer rates rising in young adults. https://www.cancer.org/latest-news/colorectal-cancer-rates-rising-in-young-adults.html
- Siegel, R. L., et al. (2023). Colorectal cancer statistics 2023. *CA: A Cancer Journal for Clinicians*, *73*(2), 103-121. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/caac.21773
